Investment Thesis
Adagio Medical is in severe financial distress with complete revenue collapse ($0), substantial operating losses (-$5.2M), and excessive leverage (4.0x debt-to-equity), indicating a non-viable business. With negative operating cash flow (-$4.1M) and limited cash runway, the company faces existential viability concerns in a capital-intensive medical devices sector requiring sustained R&D investment.
Strengths
- Maintains adequate short-term liquidity (1.85x current ratio, 1.66x quick ratio)
- Holds $12.9M cash providing near-term operational runway
- Company remains listed on Nasdaq and has not filed for bankruptcy (as of filing date)
Risks
- Complete revenue collapse (100% YoY decline to $0) with no visible recovery path or commercialization timeline
- Highly leveraged balance sheet (4.0x debt-to-equity) with $22.9M long-term debt against $5.7M stockholders equity creating default risk
- Negative operating cash flow (-$4.1M annual burn) with approximately 3-year maximum cash runway at current burn rate
- Unsustainable losses (-$5.2M operating, -$7.0M net) requiring immediate revenue resumption for survival
- Medical devices sector requires substantial R&D and regulatory approval—company lacks revenue to fund either
- Minimal insider trading activity suggests low management confidence in recovery
Key Metrics to Watch
- Revenue recognition and resumption of commercial operations
- Monthly cash burn rate and cash position depletion timeline
- Debt refinancing, restructuring, or covenant violation announcements
- Form 8-K filings for material events or strategic pivots
- Clinical trial status or regulatory pathway updates in SEC filings
Financial Metrics
Revenue
0.0
Net Income
-7.0M
EPS (Diluted)
$-0.31
Free Cash Flow
-4.1M
Total Assets
39.3M
Cash
12.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-122.2%
ROA
-17.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.85x
Quick Ratio
1.66x
Debt/Equity
4.00x
Debt/Assets
85.4%
Interest Coverage
N/A
Long-term Debt
22.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T07:33:18.346785 |
Data as of: 2026-03-31 |
Powered by Claude AI